The Drug That Delivers Chemotherapy to the Exact Cell That Needs It
Antibody-drug conjugates are biopharmaceutical constructs that combine the targeting precision of a monoclonal antibody with the cytotoxic potency of a chemotherapy payload, connecting the two components through a linker chemistry whose stability in the bloodstream and controlled release at the tumour site determines the clinical profile that differentiates successful ADCs from those whose toxicity or lack of efficacy has terminated development. The antibody component binds specifically to an antigen expressed at elevated levels on cancer cells, delivering the ADC to the tumour site through receptor-mediated internalisation, after which the linker releases the cytotoxic payload inside the cancer cell where it causes the DNA damage, tubulin disruption, or topoisomerase inhibition that kills the cell. The selective delivery of the cytotoxic payload to the antigen-expressing tumour cell allows ADCs to use chemotherapy agents at doses and potencies that would be unacceptably toxic as systemic chemotherapy, creating the therapeutic index expansion that is the commercial and clinical value proposition of the ADC drug class. The twenty approved ADCs in clinical use as of 2026, whose approvals span antigens including HER2, Trop-2, Nectin-4, BCMA, FOLR1, CD19, CD22, CD30, CD33, and CD79b across breast cancer, bladder cancer, lung cancer, blood cancers, and other indications, demonstrate the applicability of the ADC mechanism across the antigen diversity of human cancers.
The global antibody-drug conjugate market, valued at $15.41 billion in 2026 and growing at eleven percent annually toward $34.87 billion by 2034, reflects both the commercial success of the approved ADC portfolio, led by Enhertu's $4.70 billion in 2026 revenue representing twenty-eight percent of the total ADC market, and the active development pipeline whose 1,519 ongoing Phase 2 and Phase 3 trials globally represent the most active drug development pipeline in oncology by clinical trial count. The ADC sector has entered what the industry describes as a phase of rapid commercial maturation, in which the first-generation ADCs whose modest clinical activity and significant toxicity limited their commercial impact, exemplified by Pfizer's Mylotarg whose accelerated approval was withdrawn in 2010 before its eventual reapproval, have been succeeded by the second-generation ADCs whose linker and payload improvements created commercially viable products and the third-generation DXd payload ADCs whose clinical performance is redefining cancer treatment standards in HER2-positive and HER2-low breast cancer, gastric cancer, and lung cancer.
Daiichi Sankyo's DXd Platform and the Five 2026 Launches
Daiichi Sankyo is the Japanese pharmaceutical company whose DXd ADC technology platform has produced the most commercially and clinically significant ADC portfolio in the industry. Its readouts from five registrational clinical trials in 2025, whose results set up the five ADC launches that Daiichi Sankyo's commercial organisation is executing across 2026, represent the most concentrated single-company ADC commercialisation effort in pharmaceutical history. The DXd payload, an exatecan derivative topoisomerase I inhibitor whose potency and bystander killing effect, in which the payload diffuses from targeted cells to kill adjacent antigen-negative tumour cells, creates the clinical differentiation that the DESTINY-Breast04 trial demonstrated when Enhertu achieved superior outcomes in HER2-low breast cancer, a patient population that the oncology community had not previously recognised as HER2-targetable and whose identification expanded the addressable population for HER2-directed therapy from approximately fifteen percent to over fifty percent of all metastatic breast cancer cases.
Datroway, whose generic name is datopotamab deruxtecan and whose December 2024 FDA approval for HR-positive HER2-negative breast cancer was followed by EU approval in 2026 with the Trop-2 targeting antibody delivering DXd payload to the tumour cell population that the breast cancer treatment sequence reaches after first-line endocrine therapy and CDK4/6 inhibition, represents the second major commercial DXd ADC whose label expansion across lung cancer and other solid tumour indications is progressing through the clinical programme. The five DXd ADC clinical programmes that Daiichi Sankyo and AstraZeneca are advancing through their global commercialisation partnership, which encompasses Enhertu in multiple indications, Datroway in breast and lung cancer, patritumab deruxtecan targeting HER3 for EGFR-mutant NSCLC, ifinatamab deruxtecan targeting B7-H3 for small cell lung cancer, and raludotatug deruxtecan targeting CDH6 for ovarian cancer, create the pipeline breadth whose readout-to-approval-to-launch sequence in 2025 and 2026 is generating the commercial momentum that analysts project will make Daiichi Sankyo the second-largest oncology company by revenue by 2028.
Chinese ADC Development and the Western Acquisition Wave
The past twenty-four months have brought five new ADC launches to the global market, including Trastuzumab Rezetecan from Chinese developer Hengrui, Telisotuzumab Vedotin from AbbVie, Sacituzumab Tirumotecan from the Kelun-Merck collaboration, and Pivekimab Sunirine from AbbVie, reflecting the commercialisation of clinical programmes whose development has been driven by the extraordinary business development activity that has reshaped the ADC competitive landscape between 2022 and 2026. Western large pharmaceutical companies have paid premium upfront payments for de-risked Chinese ADC assets whose clinical data and manufacturing capability reduce the development risk that internal ADC programmes require, while platform acquisitions including Pfizer's $43 billion Seagen acquisition have consolidated the MMAE microtubule ADC technology platform that Seagen commercialised through its vcMMAE linker-payload combination across multiple approved products. The combination therapy patent space, in which ADC plus checkpoint inhibitor and ADC plus DNA damage response inhibitor combinations are being evaluated in the clinical trials that Daiichi Sankyo and AstraZeneca are building their next commercial moat around, represents the emerging frontier of ADC clinical development that the approved single-agent ADCs have validated as the platform for continued innovation.
Top 10 Companies in Antibody-Drug Conjugate Development and Commercialisation Globally
- Daiichi Sankyo: Japanese pharmaceutical company with five ADC launches planned in 2026 and the DXd payload platform; its Enhertu and Datroway commercial revenues and its AstraZeneca global partnership create the ADC company whose pipeline depth and commercial execution define the competitive standard that every other ADC developer is measured against.
- AstraZeneca: UK pharmaceutical company with global commercialisation partnership for Daiichi Sankyo's DXd ADC portfolio; its oncology commercial infrastructure across the US, Europe, and Asia and its combination therapy clinical programme create the commercialisation partner whose scale and oncology market relationships are critical to DXd ADC commercial performance.
- Roche (Kadcyla, Polivy): Swiss pharmaceutical company with Kadcyla trastuzumab emtansine holding 28.86 percent ADC market share in 2025 and Polivy polatuzumab vedotin for diffuse large B-cell lymphoma; its HER2 franchise leadership and its expanded access programmes in Asia Pacific and Latin America create the incumbent ADC commercial leader whose Kadcyla franchise predates the DXd generation.
- Pfizer (Seagen heritage): US pharmaceutical company with the Seagen MMAE ADC platform through its $43 billion acquisition; its Padcev enfortumab vedotin for urothelial carcinoma and Adcetris brentuximab vedotin for Hodgkin lymphoma create the vcMMAE ADC commercial portfolio whose urothelial carcinoma first-line indication is the fastest-growing ADC market segment.
- Gilead Sciences (Trodelvy): US pharmaceutical company with Trodelvy sacituzumab govitecan for Trop-2-expressing cancers; its triple-negative breast cancer and urothelial carcinoma approvals and its competition with Daiichi Sankyo's Datroway in Trop-2-targeting create the commercial rivalry whose clinical outcome data comparison is defining the Trop-2 ADC commercial positioning.
- AbbVie: US pharmaceutical company with Telisotuzumab Vedotin approval for c-Met expressing NSCLC and Pivekimab Sunirine for BPDCN; its two 2026 ADC launches and its acquisition-driven ADC portfolio expansion create the large pharmaceutical company's ADC commercial position that its oncology pipeline is building beyond its established haematology franchise.
- Jiangsu Hengrui Pharmaceuticals: Chinese pharmaceutical company with Trastuzumab Rezetecan ADC commercialisation; its Chinese domestic market and its global out-licensing of Chinese ADC assets to Western partners create the Chinese ADC developer whose commercial model of generating clinical data for Western partnership is the most commercially validated Chinese ADC strategy.
- Kelun-Biotech (Merck collaboration): Chinese biotech with Sacituzumab Tirumotecan commercialised through Merck partnership; its Trop-2 ADC clinical data and its Merck commercialisation partnership create the Chinese ADC company whose Western partnership model has produced an approved product that competes directly with Gilead's Trodelvy.
- ADC Therapeutics: Swiss ADC company with Zynlonta loncastuximab tesirine for relapsed or refractory large B-cell lymphoma; its PBD dimer payload technology whose DNA interstrand cross-linking mechanism differs from MMAE and DXd create the ADC company whose payload chemistry diversification addresses the resistance mechanisms that first and second generation ADC payloads encounter.
- Alphamab Oncology: Chinese ADC and bispecific antibody company with late-stage ADC candidates and bispecific ADC platform development; its bispecific ADC approach that uses antibody engineering to target two antigens simultaneously and its Phase 3 pipeline create the Chinese ADC innovator whose bispecific platform represents the next-generation ADC architecture that the current approved monospecific ADCs are the commercial baseline for.